Eleven Biotherapeutics Secures $20,000,000 Series A Round
-
Feed Type
-
Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=ddfe2365-b062-4963-8b9d-a6c9ab681623&Preview=1 -
Date
5/8/2012 -
Company Name
Eleven Biotherapeutics -
Mailing Address
215 First Street Cambridge, MA 02142 -
Company Description
Eleven Biotherapeutics secured Series A financing in February 2010, backed by two leading life sciences venture capital firms, Flagship Ventures and Third Rock Ventures. -
Website
http://www.elevenbio.com -
Transaction Type
Venture Equity -
Transaction Amount
$20,000,000 -
Transaction Round
Series A -
Proceeds Purposes
Proceeds from the financing will be used to advance Eleven’s first program, EBI-005, into clinical development while continuing to advance earlier stage programs generated by its proprietary AMP-Rx product engine. -
M&A Terms
-
Venture Investor
Jafco Ventures -
Venture Investor
Third Rock Ventures -
Venture Investor
Third Rock Ventures -
Venture Investor
Flagship Ventures
